Biotech Values

[DewDiligence]

MON—According to SeekingAlpha, UBS is neutral on the stock because MON has a “thinning pipeline of blockbuster products” (http://seekingalpha.com/article/319199-ubs-s-picks-for-least-attractive-industrial-stocks-part-i ). I wonder if UBS actually said this and, if so, whether the UBS analyst read and absorbed the contents of #msg-70653826.